Activating KRAS mutations, which stimulate the MAPK and AKT signaling pathways to promote cell proliferation and survival, have been associated with immune evasion and resistance to ICI therapy in CRC [11, 12]. The gene discussed is KRAS; the disease is colorectal carcinoma.